Orphan Receptor Promiscuity in the Induction of Cytochromes P450 by Xenobiotics*

Despina SmirlisDagger §, Roongsiri MuangmoonchaiDagger , Mina EdwardsDagger , Ian R. Phillips||**, and Elizabeth A. ShephardDagger DaggerDagger

From the Dagger  Department of Biochemistry and Molecular Biology, University College London, Gower Street, London WC1E 6BT, United Kingdom and the || School of Biological Sciences, Queen Mary, University of London, Mile End Road, London E1 4NS, United Kingdom

Received for publication, July 6, 2000, and in revised form, January 23, 2001



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mechanisms by which different classes of chemicals induce the same cytochrome P450 (CYP) or the same chemical differentially induces more than one CYP are not well understood. We show that in primary hepatocytes and in vivo in liver (transfected by particle-mediated delivery) two orphan nuclear receptors, constitutive androstane receptor and pregnane X receptor (PXR1), transactivate a CYP gene via the same response element in a xenobiotic-specific manner. The constitutive androstane receptor mediates the barbiturate activation of expression of CYP2B1 and CYP3A1. PXR1 activates both genes in response to synthetic steroids. To exert their effect the receptors bind to the same direct repeat site (DR4) within the phenobarbital response element of the CYP2B1 promoter and to the same DR3 site in the pregnane X response element of CYP3A1. The receptors are therefore promiscuous with respect to DNA binding but not ligand binding. Differences in enhancer half-site spacing may influence the efficiency of interactions between the receptor and the transcription machinery and hence form the basis for the differential induction of CYP2B1 and CYP3A1 in response to barbiturates and synthetic steroids.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cytochromes P450 (CYPs)1 are a superfamily of proteins, members of which catalyze the metabolism of a wide range of endogenous and exogenous chemicals (1). CYP-mediated detoxification is a key defense mechanism whereby organisms protect themselves from the potentially harmful effects of foreign hydrophobic chemicals to which they are exposed. The xenobiotics are converted to more hydrophilic compounds, which are then more easily excreted (2). Many of these xenobiotics serve as inducers of the particular CYP required for their metabolism. Induction of CYPs is mediated primarily at the transcriptional level by the interaction of ligand-nuclear receptor complexes with enhancer sequences that lie upstream of CYP gene promoters (reviewed in Refs. 3 and 4). A single CYP can be induced to different extents by different classes of chemicals, and a single chemical can differentially induce more than one CYP. For instance, CYP2B1 and CYP3A1, members of two different CYP subfamilies, can both be induced in the liver by the barbiturate phenobarbital (PB) and by the structurally unrelated synthetic pregnane pregnenolone 16alpha -carbonitrile (PCN). CYP2B1 is induced to a greater extent by PB than by PCN (5), whereas CYP3A1 is induced more highly by PCN than by PB (6). Induction of CYP2B1 in response to PB is mediated by the interaction of the constitutive androstane receptor (CAR) (7) with a phenobarbital response element (PBRE) (8, 9), and that of CYP3A1 in response to PCN by binding of the pregnane X receptor (PXR1) to a pregnane X response element (PXRE) (10-13). However, no PBRE has been identified in the flanking regions of the CYP3A1 gene, and a PXRE has not been identified in the CYP2B1 gene. The mechanisms of induction of CYP2B1 by PCN and of CYP3A1 by PB are not known.

Here we show that CAR and PXR1 can transactivate the CYP2B1 gene by interacting with the same direct repeat 4 (DR4) element of the PBRE. Similarly, the receptors transactivate the CYP3A1 gene by binding to the same DR3 element of the PXRE. In each case, the receptors transactivate gene expression in a xenobiotic-specific manner; PXR1 is activated by PCN (but not by PB) and CAR by PB (but not by PCN). The two orphan nuclear receptors thus exhibit promiscuity with respect to DNA binding but not ligand binding. The significance of the results for our understanding of the mechanisms that mediate differential induction of CYPs by xenobiotics is discussed.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmids-- The reporter plasmid (CYP2B1 PBRE)-SV40-luc was constructed by inserting the CYP2B1 PBRE sequence (-2301 to -2142 of the CYP2B1 gene) into the BglII site of the plasmid pGL3-SV40 promoter (Promega). The plasmid pRL-TK (Promega), which encodes the Renilla luciferase gene under the control of the thymidine kinase promoter, was used as a control vector to normalize the results of transient transfection assays. The reporter plasmid (CYP3A1)4-tk-CAT, containing four copies of the CYP3A1 PXRE, was kindly provided by Dr. S. Kliewer. When cells were transfected with the chloramphenicol acetyltransferase reporter plasmid, (CYP3A1)4-tk-CAT, the pSV-beta -galactosidase control vector (Promega) was used to normalize the results of transient transfection assays. Nuclear receptor expression plasmids for mouse CAR (cDM8-mCAR-beta ), mouse retinoid X receptor (RXR) (pSG5-mRXRalpha ), mouse PXR1 (pSG5-mPXR1), and newt retinoic acid receptor (RAR) (PTL-1) were provided, respectively, by Drs. D. Moore, P. Chambon, S. Kliewer, and J. Brockes.

Cell Culture and Transfection-- Primary rat hepatocytes cultured on Matrigel (1 mg/ml) (Becton Dickinson) (5 × 106 cells/60-mm plate) were transfected using TfxTM-20 reagent (Promega) according to the supplier's recommendations. Transfection mixtures (6 ml) contained 2.5 µg of reporter plasmid, 0.25 µg of control plasmid, and 0.25 µg of an expression plasmid. Cell extracts were assayed for luciferase (Dual-Luciferase reporter assay system), chloramphenicol acetyltransferase (CAT enzyme assay system), or beta -galactosidase (beta -galactosidase enzyme assay system) (all from Promega) activities according to the supplier's recommendations.

In Vivo Transfection of Liver by Biolistic Particle Delivery-- Gold particles, 25 mg (1 micron, Bio-Rad), were coated with 100 µg of DNA. The ratios of (CYP2B1 PBRE)-SV40-luc, pRL-TK and the expression plasmid (either cDM8-mCAR-beta or pSG5-mPXR1) was 10:1:1. The amount of total DNA/cartridge was 2 µg. Male Harlan Sprague-Dawley rats (200-250 g) were anesthetized and the liver shot at two different positions in a single lobe. A single dose of PB (100 mg/kg) or PCN (100 mg/kg) was given intraperitoneally as soon as suturing was complete. 24 h later the liver was removed and assayed for luciferase activity as described above.

Gel Mobility Shift Assays-- Nuclear protein extracts were prepared from the livers of untreated and PB-treated rats as described previously (14, 15). CAR, PXR1, and RXRalpha were synthesized in vitro using a TNT® transcription/translation-coupled reticulocyte lysate system (Promega) according to the supplier's recommendations. Gel mobility shift assays contained 10 mM HEPES (pH 7.6), 0.5 mM dithiothreitol, 15% (v/v) glycerol, 2.5 µg poly(dI·dC), 0.05% (v/v) Nonidet P-40, 50 mM NaCl, 1.5 µl of in vitro translated products or 5 µg of liver nuclear protein extract, and 3 × 104 cpm of a 32P-labeled double-stranded oligonucleotide. The binding reaction was performed at room temperature for 20 min. For competition assays, various amounts of unlabeled double-stranded oligonucleotide were included as indicated. The following oligonucleotides, synthesized by Amersham Pharmacia Biotech, were used as probes or competitors: the CYP2B1 nuclear receptor half-site NR1 (DR4), 5'-TCTGTACTTTCCTGACCTT-3'; the CYP3A1 PXRE (DR3), 5'-AGACAGTTCATGAAGTTCATCT-3'. For supershift assays, rabbit polyclonal antibodies against RXRalpha (SC-553x) (2 µg) or PXR1 (SC-7737x) (2 µg) (Santa Cruz Biotechnology, Inc.) were added 15 min after the start of the binding reaction. Incubation was continued for another 20 min.

To assess binding of nuclear receptor/RXRalpha heterodimers to DNA response elements, in vitro transcription/translation reaction master mixes were prepared, one containing 35S-labeled methionine (RedivueTM [L-35S]methionine, Amersham Pharmacia Biotech) and the other, unlabeled methionine. Each master mix was split into equal batches and the appropriate expression vector added. Unlabeled and labeled transcription/translations were performed in parallel. Radiolabeled proteins were assessed by SDS-polyacrylamide gel electrophoresis and their specific activity determined. Using the methionine content of each expressed protein, the volumes of unlabeled reticulocyte lysate mix that would contain equal amounts of CAR, PXR1, and RXRalpha were calculated. Gel mobility shift assays were performed using a 1:1 molar ratio of unlabeled RXRalpha and either CAR or PXR1 and, as DNA probe, a radiolabeled double-stranded oligonucleotide specifying the CYP2B1 NR1 or the CYP3A1 PXRE.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

CAR and PXR1 Transactivate CYP2B1 Expression via the PBRE in Response to PB and PCN, Respectively-- In primary rat hepatocytes, both PB and PCN increase the expression of a reporter gene under the control of the CYP2B1 PBRE (Fig. 1A), suggesting that induction of CYP2B1 by PCN is mediated by the interaction of either CAR or the ligand's cognate receptor, PXR1, with the PBRE. To investigate this possibility, we tested the effect of the xenobiotics on the expression of the CYP2B1 PBRE-reporter construct in hepatocytes cotransfected with an expression vector for either CAR or PXR1 (Fig. 1A). Reporter gene expression was constitutively increased almost 5-fold by CAR but not by PXR1. In cells cotransfected with a PXR1 expression vector, reporter gene expression was increased 6-fold by PCN but not by PB. In cells cotransfected with a CAR expression vector, PB increased gene expression more than 3-fold above the level mediated constitutively by CAR, whereas PCN had no effect. Therefore induction of CYP2B1 gene expression in response to PB and PCN is mediated, respectively, by the interaction of CAR and PXR1 with the PBRE.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 1.   PB and PCN induce CYP2B1 expression via the PBRE. A, primary hepatocytes were transfected with a (CYP2B1 PBRE)-SV40-luc reporter construct containing one copy of the CYP2B1 PBRE with or without (No E.P.) expression vectors for CAR or PXR1. Transfected cells were treated with vehicle (DMSO) alone or with PB or PCN and then assayed for luciferase activity. *, significantly different from the corresponding control value, p < 0.05, (two-tail, paired Student's t test). B, gel mobility shift assay using as probe the radiolabeled CYP2B1 NR1 sequence and equimolar amounts of in vitro synthesized RXRalpha , PXR1, or CAR as indicated. C, gel mobility shift assays of rat liver nuclear proteins using as probe a radiolabeled double-stranded oligonucleotide corresponding to either the CYP2B1 NR1 or the CYP3A1 PXRE. Assays were done as indicated in the presence (+) or absence (-) of antibodies against PXR1 (PXR1 Ab) or RXRalpha (RXR Ab) or of a 100-fold molar excess of an unlabeled double-stranded oligonucleotide competitor corresponding to the NR1 site or the PXRE. D, intact rat liver was transfected with the reporter construct (CYP2B1 PBRE)-SV40-luc with or without (No E.P.) expression plasmids for CAR or PXR1. Animals were treated with vehicle (DMSO) alone or with PB or PCN. Luciferase activity was assayed 24 h post-operative.

We next determined whether CAR and PXR1 bind to the same or different sites within the PBRE. CYP2B PBREs contain two DR4 nuclear receptor half-sites, NR1 (5'-TGTACT TTCC TGACCT-3') and NR2 (5'-TCAACT TTCC TGACCT-3'), separated by a NF-1 (nuclear factor-1) site (8, 9, 16). PXR1, produced by in vitro transcription/translation, was found to bind, as a heterodimer with RXRalpha , to the NR1 element (Fig. 1B), the same site within the PBRE to which CAR binds as a RXRalpha heterodimer (Fig. 1B) (9). Neither CAR nor PXR1 binds to the rat CYP2B1 NR2 site when heterodimerized with mouse RXRalpha (17). However, when heterodimerized with human RXR, CAR can bind to the NR2 site of the mouse Cyp2b10 gene (18).

Complexes formed between the NR1 site and liver nuclear proteins were competed by the PXRE of CYP3A1 and were supershifted by antibodies against PXR1 and RXRalpha (Fig. 1C). These results are similar to those obtained using the CYP3A1 PXRE as probe (Fig. 1C) and confirm the interaction of PXR1/RXRalpha heterodimers with the NR1 site of the PBRE.

To determine the effect of the receptors on CYP2B1 expression in vivo we performed transfection experiments in liver (Fig. 1D). A CYP2B1 PBRE-reporter plasmid, together with expression vectors for either PXR1 or CAR, was introduced into rat liver by biolistic particle-mediated DNA transfer. Reporter gene expression was increased constitutively by CAR but not by PXR1. The CAR-mediated transactivation of reporter gene expression was increased further in response to PB but not to PCN. Conversely, the presence of PXR1 stimulated the induction of gene expression by PCN, whereas it decreased the effect of PB, presumably by competition with endogenous CAR for binding to the PBRE (see Fig. 2F). The results are qualitatively similar to those obtained in hepatocyte cultures (see Fig. 1A) and confirm that in vivo both PXR1 and CAR are able to transactivate gene expression via interaction with the same CYP2B1 enhancer element (the NR1 of the PBRE) in response to PCN and PB, respectively. Hence, the regulation of CYP2B1 expression by xenobiotics involves cross-talk between ligand-receptor complexes.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 2.   CAR and PXR1 bind to the same sites within the promoters of the CYP2B1 and CYP3A1 genes. Gel mobility shift assays of in vitro synthesized CAR/RXR (A) and PXR/RXR (B) using as probes radiolabeled double-stranded oligonucleotides corresponding to CYP2B1 NR1 (A) or CYP3A1 PXRE (B). Assays were done as indicated in the absence or presence of increasing amounts of unlabeled double-stranded oligonucleotide competitors corresponding to the NR1 or PXRE sites. L represents unprogrammed reticulocyte lysate. The arrows indicate a nonspecific complex formed between the probe and proteins present in unprogrammed lysate. C, gel mobility shift assays using as probes radiolabeled double-stranded oligonucleotides corresponding to either CYP2B1 NR1 or CYP3A1 PXRE and increasing amounts of in vitro synthesized CAR/RXR (C/R) or PXR/RXR (P/R) as indicated. The arrow indicates a nonspecific complex formed with proteins in the unprogrammed lysate. D, relative binding affinities of CAR for NR1 and PXRE (determined from A). E, relative binding affinities of PXR for PXRE and NR1 (determined from B). F, primary hepatocytes (5 × 106/60-mm plate) were cotransfected with 2.5 µg of the reporter construct (CYP2B1 PBRE)-SV40-luc, 0.25 µg of the control plasmid pRL-TK, 0.25 µg of an expression plasmid for CAR, and increasing amounts of an expression vector for PXR1 () or RAR (black-diamond ). Cells were treated with PB and then assayed for luciferase activity. The results were plotted as a percentage of CAR-mediated PB activation of reporter gene expression in the absence of competitor receptor and were normalized against the expression of the Renilla luciferase reporter gene cotransfected as an internal standard.

We next investigated the relative affinity with which CAR and PXR bind to the DR4 CYP2B1 NR1 and DR3 CYP3A1 PXRE sites. Competitive gel shift assays were performed in which constant amounts of in vitro transcribed and translated CAR and RXRalpha or PXR and RXRalpha were incubated in the presence of unlabeled NR1 or PXRE with radiolabeled oligonucleotides specifying either the NR1 or PXRE sites. The CAR·RXRalpha -NR1 complex was competed more effectively by NR1 than by PXRE (Fig. 2A), whereas the PXR·RXRalpha -PXRE complex was competed more effectively by the PXRE than by NR1 (Fig. 2B). When increasing amounts of in vitro synthesized CAR/RXRalpha proteins were incubated with NR1 or PXRE probes, radiolabeled to the same specific activity, the protein-DNA complex formed on the NR1 site was more abundant than on the PXRE site (Fig. 2C). Conversely, PXR/RXRalpha bound more effectively to the PXRE than to the NR1 site (Fig. 2C). A comparison of relative binding affinities showed that CAR/RXRalpha bound to the NR1 site with a 2-fold greater affinity than to the PXRE (Fig. 2D) and that the affinity of PXR/RXRalpha for PXRE was about three times that for NR1 (Fig. 2E).

The ability of CAR and PXR1 to bind to the same response element, albeit with different affinities, suggests that the receptors will compete with each other for binding to this site in vivo and thus exhibit functional cross-talk. This theory was supported by the finding that CAR-mediated transactivation of a CYP2B1 PBRE-reporter construct in response to PB was inhibited by PXR1 in a dose-dependent manner (Fig. 2F). Reporter gene activity was decreased by about 60% when PXR and CAR expression plasmids were present in equimolar amounts and by as much as 80% by a 5-fold molar excess of PXR over CAR plasmid. As a control for squelching, hepatocytes were cotransfected with expression vectors for CAR and RAR, another nuclear receptor that heterodimerizes with RXRalpha , and whose cDNA was cloned into the same type of expression vector as that used for PXR, namely pSG5. RAR decreased reporter gene expression by ~25% (Fig. 2F). Therefore, although some of the inhibitory effects of PXR may be due to competition with CAR for binding to RXRalpha , the majority most likely is due to competition with CAR for binding to the NR1 site of the PBRE.

CAR and PXR1 Transactivate CYP3A1 Expression via the PXRE in Response to PB and PCN, Respectively-- In response to PCN, PXR1 stimulates CYP3A1 gene expression by binding to a DR3 PXRE (5'-TGAACT TCA TGAACT-3') (10, 13). The PXRE of CYP3A1 and the NR1 of the CYP2B1 PBRE were found to compete in gel mobility shift assays for binding to rat liver nuclear proteins (Fig. 1C). Furthermore, in vitro synthesized CAR bound as a heterodimer with RXRalpha to the PXRE (Fig. 2, A and C), suggesting that PXR1 and CAR may transactivate CYP3A1 by binding to the same site within the gene's promoter. To determine whether CAR can mediate PB-induced transactivation via the PXRE, hepatocytes were cotransfected with a CYP3A1 PXRE-reporter plasmid and an expression vector for either CAR or PXR1 (Fig. 3). In cells cotransfected with CAR, reporter gene expression was induced 10-fold in response to PB, whereas PCN had little effect. In contrast, in cells cotransfected with PXR1, gene expression was increased 11-fold by PCN but not by PB. Thus, as is the case for the CYP2B1 gene, PXR1 and CAR bind to the same enhancer element within the CYP3A1 promoter (the PXRE) to activate gene expression in response to two different xenobiotics, PCN and PB, respectively. Each receptor can therefore mediate the xenobiotic induction of members of two different CYP subfamilies by interacting with a different response element within each of the corresponding genes. The receptors are therefore promiscuous with respect to DNA binding. However, they are specific with respect to their xenobiotic activator; PXR1 is activated by PCN (but not by PB) and CAR by PB (but not PCN).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   CAR and PXR1 transactivate via the same CYP3A1 DNA element. Primary hepatocytes were transfected with the reporter plasmid (CYP3A1)4-tk-CAT and the control vector pSV-beta -galactosidase with or without (No E.P.) expression plasmids for CAR or PXR1. Cells were treated with vehicle (DMSO) alone or with PB or PCN and then assayed for chloramphenicol acetyltransferase and beta -galactosidase activities. *, p < 0.01; **, p < 0.05, compared with the corresponding control value (two-tail paired Student's t test).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mechanisms by which different classes of chemicals induce the same CYP or the same chemical differentially induces more than one CYP are not well understood. Here we show that in primary hepatocytes and in vivo in the liver two orphan nuclear receptors, CAR and PXR1, transactivate a CYP gene via the same response element in a xenobiotic-specific manner. CAR mediates barbiturate activation of expression of CYP2B1 and CYP3A1. PXR1 activates both genes in response to synthetic steroids. To exert their effect the receptors bind to the same DR4 site within the PBRE of the CYP2B1 promoter and to the same DR3 site in the PXRE of CYP3A1. The receptors are therefore promiscuous with respect to DNA binding.

In vivo CYP3A1 is less inducible (3-fold) by PB than is CYP2B1 (50-to 100-fold) (6, 19). Similarly, PCN is a less potent inducer of CYP2B1 (3-fold) than of CYP3A1 (10-to 20-fold) (6). The deletion of a single base pair from a nuclear receptor half-site spacer region will alter the displacement (by 3.4 Å) and the rotation angle (by 36o) between the two half-site complexes (20). Thus, the dimerization interface between CAR and RXRalpha (and between PXR1 and RXRalpha ) when bound to the DR4 CYP2B1 NR1 will be different from that of the proteins when bound to the DR3 CYP3A1 PXRE. In addition, the CAR/RXRalpha heterodimer binds to the CYP2B1 NR1 more effectively than does the PXR1/RXRalpha heterodimer, and PXR1/RXRalpha binds more effectively to the PXRE than does CAR/RXRalpha (Fig. 2). Therefore, the length of the half-site spacer in the nuclear receptor response element may influence both the binding affinity of the receptor heterodimer and its ability to interact with the transcriptional machinery and may thus provide a basis for the differential induction of CYP2B1 and CYP3A1 in response to PB or PCN.

It has been shown (21) that in HepG2 cells stably transfected with CAR, the expression of a reporter gene under the control of the human CYP3A4 PXRE, an everted repeat-6 (ER6) element, was down-regulated by 16 (5alpha ) androsten-3alpha -ol (androstenol), an inverse agonist of CAR (22), and restored to its original level by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP). The CYP3A4 ER6 PXRE contains a DR4 element similar to the DR4 element of the NR1 site of the PBRE of CYP2B genes. The discrimination of binding of orphan receptors to direct repeat response elements is dictated largely by the length of the inter-half-site spacer (23). It is not surprising, therefore, that CAR is able to bind to the DR4 CYP3A4 PXRE. Our results demonstrate that CAR and PXR1 can bind to and transactivate via both DR4 and DR3 elements. Furthermore, we show that in primary hepatocytes, pretreatment with an inverse agonist of CAR is not required to obtain CAR-mediated PB induction of gene expression via either the CYP2B1 PBRE or the CYP3A1 PXRE. In agreement with our results, Moore et al. (24) found that the mouse isoform of PXR transactivates a CYP3A4-reporter gene in response to PCN but not to PB. These workers also found that neither human nor mouse CAR was able to transactivate a CYP3A4-reporter gene in response to PB. However, these experiments were performed in CV-1 cells, which, unlike primary hepatocytes, do not support PB-induced CAR-mediated transactivation of gene expression (17).

Several models can be proposed to explain how a single CYP can be induced by different classes of chemicals and how a single chemical can differentially induce more than one CYP. For instance, CYP genes may contain multiple xenobiotic response elements, each of which binds a distinct nuclear receptor. In this model, structurally related compounds may bind to the same receptor, but different classes of chemical would interact with different receptors. For example, many polycyclic aromatic hydrocarbons are able to interact with the aryl hydrocarbon receptor, whereas several steroids can bind to the PXR1. Differential induction of CYP genes by the same xenobiotic may be the result of differences in the sequence or environment of a particular response element in different genes. In a second model, a receptor can bind structurally unrelated xenobiotics before interacting with its cognate response element. For example, chlortrimazole and TCPOBOP have been shown to bind to human PXR and transactivate gene expression via a CYP3A4 PXRE (24). Differences in receptor conformation, as a result of binding different chemicals, may account for differential induction responses. In this model, differential induction of CYP genes by the same chemical would result from binding of the chemical to different receptors, each of which then binds to its cognate response element and transactivates with a different efficiency. The results presented in this paper support a third model in which different receptors interact with the same response element, i.e. the receptors are promiscuous with respect to DNA binding but not ligand binding. Differences in the interface between an orphan receptor and its dimerization partner, RXRalpha , because of differences in the half-site spacing of response elements may influence the efficiency with which the heterodimer interacts with the transcriptional machinery and hence provide the basis for the differential induction of CYP genes by the same chemical. These models are not mutually exclusive, and all three could be involved in regulating the expression of a particular CYP gene.

CAR was originally shown to bind to and transactivate gene expression via DR2 and DR5 retinoic acid response elements (7, 25, 26). Subsequently, it was found that the receptor could transactivate via a DR4 element in CYP2B genes (9) and a DR1 peroxisome proliferator response element in the enoyl-CoA hydratase/3-hydroxy acyl-CoA dehydrogenase gene (27). Here we show that CAR can transactivate CYP gene expression in response to PB via DR4 and DR3 elements. CAR is thus extremely promiscuous with respect to DNA binding and must therefore have a great flexibility in its interactions with its heterodimerization partner, RXRalpha , and with components of the transcription machinery.

PB regulates the transcription of 30 or more genes in the liver (28). The recent production of a CAR knock-out mouse confirms that this orphan nuclear receptor mediates the induction of CYP2B by phenobarbital (29). It will be of interest to determine whether all PB-inducible genes are activated by CAR and to identify the enhancer site permutations to which this receptor and others, such as PXR1, can bind in the promoters of xenobiotic-regulated genes.

The detoxification of xenobiotics is necessary for survival. The evolution of orphan receptors that exhibit versatility with respect to the regulatory elements to which they bind in response to xenobiotics has clear advantages for the ability of organisms to protect themselves against potentially harmful foreign chemicals by enabling selective induction of the enzymes required to metabolize such compounds. However, competition of receptors for the same response element may lead to adverse drug-drug or xenobiotic-drug interactions.

    ACKNOWLEDGEMENTS

We thank Drs. D. Moore, S. Kliewer, P. Chambon, and J. Brockes for kindly providing expression or reporter plasmids and Drs. J. Brockes and C. Velloso for help with in vivo transfections.

    FOOTNOTES

* This work was supported by Grant 042495 from the Wellcome Trust.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipient of a Wellcome Trust Toxicology Prize studentship.

Recipient of a scholarship from the Royal Thai Government. Present address: Dept. of Clinical Chemistry, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand 50200.

Dagger Dagger To whom correspondence may be addressed: Dept. of Biochemistry and Molecular Biology, University College London, Gower Street, London WC1E 6BT, UK. Tel.: +44-20-7679-2321; Fax: +44-20-7679-7193; E-mail: e.shephard@ucl.ac.uk.

** To whom correspondence may also be addressed: School of Biological Sciences, Queen Mary, University of London, Mile End Rd., London E1 4NS, UK. Tel.: +44-20-7882-6338; Fax: +44-20-8983-0531; E-mail: I.R.Phillips@qmw.ac.uk.

Published, JBC Papers in Press, January 24, 2001, DOI 10.1074/jbc.M005930200

    ABBREVIATIONS

The abbreviations used are: CYP, cytochrome P450; PB, phenobarbital; PCN, pregnenolone 16alpha -carbonitrile; CAR, constitutive androstane receptor; CAT, chloramphenicol acetyltransferase; PBRE, phenobarbital response element; PXR1, pregnane X receptor; PXRE, pregnane X response element; DR, direct repeat; RXRalpha , retinoid X receptor alpha ; RAR, retinoic acid receptor; NR, nuclear receptor; TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Guengerich, F. P. (ed) (1987) Mammalian Cytochromes P450 , Vol. I and II , CRC Press Inc., Boca Raton, FL
2. Gonzalez, F. J. (1989) Pharmacol Rev. 40, 243-288[Medline] [Order article via Infotrieve]
3. Waxman, D. J. (1999) Arch. Biochem. Biophys. 369, 11-23[CrossRef][Medline] [Order article via Infotrieve]
4. Honkakoski, P., and Negishi, M. (2000) Biochem. J. 347, 321-337[CrossRef][Medline] [Order article via Infotrieve]
5. Phillips, I. R., Shephard, E. A., Rabin, B. R., Ashworth, A., Bayney, R. M., and Pike, S. F. (1985) in Drug Metabolism, Molecular Approaches and Pharmacological Implications (Siest, G., ed) , pp. 93-102, Pergamon Press, Oxford
6. Heuman, D. M., Gallagher, E. J., Barwick, J. L., Elshourbagy, N. A., and Guzelian, P. S. (1982) Mol. Pharmacol. 21, 753-760[Abstract]
7. Choi, H. S., Chung, M., Tzameli, I., Simha, D., Lee, Y. K., Seol, W., and Moore, D. D. (1997) J. Biol. Chem. 272, 23565-23571[Abstract/Free Full Text]
8. Trottier, E., Belzil, A., Stoltz, C., and Anderson, A. (1995) Gene 158, 263-268[CrossRef][Medline] [Order article via Infotrieve]
9. Honkakoski, P., Zelko, I., Sueyoshi, T., and Negishi, M. (1998) Mol. Cell. Biol. 18, 5652-5658[Abstract/Free Full Text]
10. Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., Perlmann, T., and Lehmann, J. M. (1998) Cell 92, 73-82[Medline] [Order article via Infotrieve]
11. Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydow-Backman, M., Ohlsson, R., Postlind, H., Blomquist, P., and Berkenstam, A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 12208-122013[Abstract/Free Full Text]
12. Blumberg, B., Sabbagh, W., Jr., Juguilon, H., Bolado, J., Jr., van Meter, C. M., Ong, E. S., and Evans, R. M. (1998) Genes Dev. 12, 3195-3205[Abstract/Free Full Text]
13. Quattrochi, L. C., Yockey, C. B., Barwick, J. L., and Guzelian, P. S. (1998) Arch. Biochem. Biophys. 349, 251-260[CrossRef][Medline] [Order article via Infotrieve]
14. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract]
15. Dell, H., Wong, S. C., Phillips, I. R., and Shephard, E. A. (1998) in Methods in Molecular Biology (Phillips, I. R. , and Shephard, E. A., eds), Vol. 107 , pp. 381-394, Humana Press, Totowa, NJ
16. Liu, S., Park, Y., Rivera-Rivera, I., Li, H., and Kemper, B. (1998) DNA Cell Biol. 17, 461-470[Medline] [Order article via Infotrieve]
17. Muangmoonchai, R., Smirlis, D., Wong, S.-C., Edwards, M., Phillips, I. R., and Shephard, E. A. (2001) Biochem. J. 355, 71-78[CrossRef][Medline] [Order article via Infotrieve]
18. Tzameli, I., Pissios, P., Schuetz, E. G., and Moore, D. D. (2000) Mol. Cell. Biol. 20, 2951-2958[Abstract/Free Full Text]
19. Waxman, D. J., and Azaroff, L. (1992) Biochem. J. 281, 577-592[Medline] [Order article via Infotrieve]
20. Rastinejad, F. (1998) in Molecular Biology of Steroid and Nuclear Hormone Receptors (Freedman, L., ed) , pp. 105-132, Birkhäuser, Boston
21. Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., and Negishi, M. (1999) J. Biol. Chem. 274, 6043-6046[Abstract/Free Full Text]
22. Forman, B. M., Tzameli, I., Choi, H. S., Chen, J., Simha, D., Seol, W., Evans, R. M., and Moore, D. D. (1998) Nature 395, 612-615[CrossRef][Medline] [Order article via Infotrieve]
23. Glass, C. K. (1994) Endocr. Rev. 15, 391-407[Medline] [Order article via Infotrieve]
24. Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., Collins, J. L., and Kliewer, S. A. (2000) J. Biol. Chem. 275, 15122-15127[Abstract/Free Full Text]
25. Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D., and Moore, D. D. (1994) Mol. Cell. Biol. 14, 1544-1551[Abstract]
26. Onate, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (1995) Science 270, 1354-1357[Abstract]
27. Kassam, A., Winrow, C. J., Fernandez-Rachubinski, F., Capone, J. P., and Rachubinski, R. A. (2000) J. Biol. Chem. 275, 4345-4350[Abstract/Free Full Text]
28. Frueh, F. W., Zanger, U. M., and Meyer, U. A. (1997) Mol. Pharmacol. 51, 363-369[Abstract/Free Full Text]
29. Wei, P., Zhang, J., Egan-Hafley, M., Liang, S., and Moore, D. D. (2000) Nature 407, 920-923[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.